Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Kellsye P FabianMichelle R PadgetRika FujiiJeffrey SchlomJames W HodgePublished in: Journal for immunotherapy of cancer (2021)
The hexatherapy regimen is a strategic combination of immuno-oncology agents that can engage, expand, enable, and evolve the immune response and can provide therapeutic benefits in both MC38-CEA (warm) and 4T1 (cool) tumor models.